Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)

Next Previous
Search
Trial Profile

A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Cobimetinib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MODUL
  • Sponsors Roche

    • Most Recent Events

    • 03 Jul 2021 Results assessing efficacy, safety and exploratory biomarker findings from Cohort 1 of this trial presented at the 23rd World Congress on Gastrointestinal Cancer
    • 08 Jun 2021 Exploratory biomarker findings from cohort 2 results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2021 This trial has been completed in Solvenia and France (End Date: 24 Mar 2021), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top